Sutro Biopharma (FRA:S090) FFO


FRA:S090 Sutro Biopharma Inc FRA:S090
46 GF Score
Price €24.80
GF Value €10.36
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sutro Biopharma FFO?

FFO (Funds from operations) only applies to REITs.

FRA:S090
46GF Score
Sutro Biopharma Inc FRA:S090
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sutro Biopharma (FRA:S090) Overvalued in 2026?

Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued. The current stock price of €24.80 is trading 139.4% above its estimated GF Value™ of €10.36. GuruFocus considers Sutro Biopharma to be Significantly Overvalued.

Key valuation signals for FRA:S090:

  • FFO:
  • GF Value™: €10.36 vs. price of €24.80 (139.4% above fair value)
  • GF Score™: 46/100 with 4 warning signs

No single metric tells the full story. See the FRA:S090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sutro Biopharma Business Description

Other Exchanges STRO:USA
Address 111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
46GF Score

Get the complete analysis for FRA:S090

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€24.80
Price
€10.36
GF Value